Antiherpetic drugs: a potential way to prevent Alzheimer's disease?
Alzheimer’s disease
Antiherpetic drugs
Antimicrobial
Dementia
Herpesvirus
Infection
Medico-administrative databases
Prevention
Treatment
Vascular dementia
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
07 01 2022
07 01 2022
Historique:
received:
02
04
2021
accepted:
15
12
2021
entrez:
8
1
2022
pubmed:
9
1
2022
medline:
11
3
2022
Statut:
epublish
Résumé
Considering the growing body of evidence suggesting a potential implication of herpesviruses in the development of dementia, several authors have questioned a protective effect of antiherpetic drugs (AHDs) which may represent a new means of prevention, well tolerated and easily accessible. Subsequently, several epidemiological studies have shown a reduction in the risk of dementia in subjects treated with AHDs, but the biological plausibility of this association and the impact of potential methodological biases need to be discussed in more depth. Using a French medico-administrative database, we assessed the association between the intake of systemic AHDs and the incidence of (i) dementia, (ii) Alzheimer's disease (AD), and (iii) vascular dementia in 68,291 subjects over 65 who were followed between 2009 and 2017. Regarding potential methodological biases, Cox models were adjusted for numerous potential confounding factors (including proxies of sociodemographic status, comorbidities, and use of healthcare) and sensitivity analyses were performed in an attempt to limit the risk of indication and reverse causality biases. 9.7% of subjects (n=6642) had at least one intake of systemic AHD, and 8883 incident cases of dementia were identified. Intake of at least one systemic AHD during follow-up was significantly associated with a decreased risk of AD (aHR 0.85 95% confidence interval [0.75-0.96], p=0.009) and, to a lesser extent with respect to p values, to both dementia from any cause and vascular dementia. The association with AD remained significant in sensitivity analyses. The number of subjects with a regular intake was low and prevented us from studying its association with dementia. Taking at least one systemic AHD during follow-up was significantly associated with a 15% reduced risk of developing AD, even after taking into account several potential methodological biases. Nevertheless, the low frequency of subjects with a regular intake questions the biological plausibility of this association and highlights the limits of epidemiological data to evaluate a potential protective effect of a regular treatment by systemic AHDs on the incidence of dementia.
Sections du résumé
BACKGROUND
Considering the growing body of evidence suggesting a potential implication of herpesviruses in the development of dementia, several authors have questioned a protective effect of antiherpetic drugs (AHDs) which may represent a new means of prevention, well tolerated and easily accessible. Subsequently, several epidemiological studies have shown a reduction in the risk of dementia in subjects treated with AHDs, but the biological plausibility of this association and the impact of potential methodological biases need to be discussed in more depth.
METHODS
Using a French medico-administrative database, we assessed the association between the intake of systemic AHDs and the incidence of (i) dementia, (ii) Alzheimer's disease (AD), and (iii) vascular dementia in 68,291 subjects over 65 who were followed between 2009 and 2017. Regarding potential methodological biases, Cox models were adjusted for numerous potential confounding factors (including proxies of sociodemographic status, comorbidities, and use of healthcare) and sensitivity analyses were performed in an attempt to limit the risk of indication and reverse causality biases.
RESULTS
9.7% of subjects (n=6642) had at least one intake of systemic AHD, and 8883 incident cases of dementia were identified. Intake of at least one systemic AHD during follow-up was significantly associated with a decreased risk of AD (aHR 0.85 95% confidence interval [0.75-0.96], p=0.009) and, to a lesser extent with respect to p values, to both dementia from any cause and vascular dementia. The association with AD remained significant in sensitivity analyses. The number of subjects with a regular intake was low and prevented us from studying its association with dementia.
CONCLUSIONS
Taking at least one systemic AHD during follow-up was significantly associated with a 15% reduced risk of developing AD, even after taking into account several potential methodological biases. Nevertheless, the low frequency of subjects with a regular intake questions the biological plausibility of this association and highlights the limits of epidemiological data to evaluate a potential protective effect of a regular treatment by systemic AHDs on the incidence of dementia.
Identifiants
pubmed: 34996520
doi: 10.1186/s13195-021-00950-0
pii: 10.1186/s13195-021-00950-0
pmc: PMC8742322
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3Informations de copyright
© 2022. The Author(s).
Références
Neuron. 2018 Jul 11;99(1):64-82.e7
pubmed: 29937276
J Alzheimers Dis. 2008 May;13(4):421-35
pubmed: 18487850
Alzheimers Dement. 2018 Dec;14(12):1602-1614
pubmed: 30314800
Invest Ophthalmol Vis Sci. 2005 Jan;46(1):241-7
pubmed: 15623779
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):954-962
pubmed: 28544284
J Am Acad Dermatol. 2006 Aug;55(2):225-32
pubmed: 16844503
Prog Lipid Res. 2006 Jan;45(1):73-90
pubmed: 16406033
J Eur Acad Dermatol Venereol. 2007 Nov;21(10):1398-403
pubmed: 17958848
Biochem Soc Trans. 1998 May;26(2):273-7
pubmed: 9649761
Rev Epidemiol Sante Publique. 2010 Aug;58(4):286-90
pubmed: 20598822
Eur J Neurol. 2021 Jun;28(6):1840-1848
pubmed: 33657269
J Alzheimers Dis. 2016 Oct 4;54(3):859-878
pubmed: 27392871
J Infect Dis. 2015 Jan 15;211(2):230-7
pubmed: 25108028
Transl Psychiatry. 2021 Jul 31;11(1):414
pubmed: 34333531
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jan;105(1):43-50
pubmed: 17703961
Brain. 2014 Apr;137(Pt 4):1167-75
pubmed: 24578544
Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12119
pubmed: 33614892
Neuroreport. 2010 Oct 6;21(14):922-7
pubmed: 20683212
PLoS One. 2017 Nov 22;12(11):e0188490
pubmed: 29166672
Ann Intern Med. 2019 Mar 19;170(6):398-406
pubmed: 30856654
J Virol. 2020 Apr 16;94(9):
pubmed: 32075924
Alzheimers Res Ther. 2017 Mar 4;9(1):14
pubmed: 28259169
PLoS Pathog. 2019 Mar 14;15(3):e1007617
pubmed: 30870531
Therapie. 2017 Sep;72(4):415-420
pubmed: 28579364
Fundam Clin Pharmacol. 2016 Dec;30(6):616-624
pubmed: 27351637
Alzheimers Dement (N Y). 2021 Jun 09;7(1):e12187
pubmed: 34136638
J Alzheimers Dis. 2008 May;13(4):393-405
pubmed: 18487848
Alzheimers Dement. 2020 Jan;16(1):200-208
pubmed: 31914220
Curr Opin Immunol. 2014 Aug;29:93-6
pubmed: 24908174
J Alzheimers Dis. 2018;62(4):1495-1506
pubmed: 29504537
Nat Genet. 2019 Mar;51(3):414-430
pubmed: 30820047
J Alzheimers Dis. 2015;47(2):351-64
pubmed: 26401558
J Clin Psychiatry. 2018 Jan/Feb;79(1):
pubmed: 29244265
Neurotherapeutics. 2018 Apr;15(2):417-429
pubmed: 29488144
PLoS One. 2011;6(10):e25152
pubmed: 22003387
Basic Clin Pharmacol Toxicol. 2018 May;122(5):451-459
pubmed: 29265740
Front Aging Neurosci. 2018 Oct 19;10:324
pubmed: 30405395
J Alzheimers Dis. 2008 Jul;14(3):259-69
pubmed: 18599953
Int J Alzheimers Dis. 2011;2011:501862
pubmed: 22254144
Exp Gerontol. 2007 Jun;42(6):563-70
pubmed: 17337145
J Med Virol. 2012 Nov;84(11):1797-802
pubmed: 22997083
Front Aging Neurosci. 2018 Mar 06;10:48
pubmed: 29559905
PLoS One. 2010 Mar 03;5(3):e9505
pubmed: 20209079
PLoS One. 2019 May 9;14(5):e0215553
pubmed: 31071098
Sex Transm Infect. 2005 Apr;81(2):103-7
pubmed: 15800084
Eur Arch Psychiatry Clin Neurosci. 2021 Aug;271(5):987-997
pubmed: 32613564
Neurochem Int. 2011 Feb;58(3):301-20
pubmed: 21167244
Neurochem Int. 2008 May;52(6):920-34
pubmed: 18164103